Skip to content

Study · Not a test of the peptide alone · 2023

10 results

Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1.

Robert C, Lebbé C, Lesimple T, Lundström E, Nicolas V, Gavillet B, Crompton P, Baroudjian B, Routier E, Lejeune FJ

Clinical cancer research : an official journal of the American Association for Cancer Research1 Mar 2023Cited by 22 (Europe PMC)

PMID36516188 (opens in a new tab)DOI10.1158/1078-0432.ccr-22-2812 (opens in a new tab)PepBankPUB-36516188
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialSafety outcome

    In anti-PD-1-resistant melanoma, the triptorelin-containing combination produced no grade 4 or 5 adverse events.

    In plain wordsIn resistant melanoma, no grade 4 or 5 adverse events occurred with the triptorelin-containing combination.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableGrade 4 or 5 adverse events
    Study

    n = 14

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    There were no grade 4 or 5 AEs.
    2 context sentences
    Summary · context
    This phase I study evaluated the safety, efficacy, and pharmocodynamics of androgen deprivation with the gonadotropin releasing hormone (GnRH) agonist triptorelin combined with nivolumab in male patients with melanoma resistant to anti-PD-1.
    Summary · context
    Adult male patients with advanced melanoma who progressed under anti-PD-1 containing regimens received triptorelin 3.75 mg every 4 weeks, nivolumab 3 mg/kg every 2 weeks, and bicalutamide 50 mg once daily during the first 28 days.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialSafety outcome

    In anti-PD-1-resistant melanoma, five grade three adverse events occurred in four patients receiving the triptorelin-containing combination.

    In plain wordsIn resistant melanoma, five grade three adverse events occurred in four patients receiving the triptorelin-containing combination.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableGrade three adverse events
    Study

    n = 14

    Outcome group
    Adverse events · Whole body

    Measurements

    Grade 3 adverse events
    5 events
    combination regimen, 14 patients
    Patients with grade 3 adverse events
    4 patients
    combination regimen, 14 patients

    Source sentences

    Summary
    Five grade three AEs were reported in 4 patients.
    2 context sentences
    Summary · context
    This phase I study evaluated the safety, efficacy, and pharmocodynamics of androgen deprivation with the gonadotropin releasing hormone (GnRH) agonist triptorelin combined with nivolumab in male patients with melanoma resistant to anti-PD-1.
    Summary · context
    Adult male patients with advanced melanoma who progressed under anti-PD-1 containing regimens received triptorelin 3.75 mg every 4 weeks, nivolumab 3 mg/kg every 2 weeks, and bicalutamide 50 mg once daily during the first 28 days.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In resistant melanoma, one patient with a pancreatic metastasis had a RECIST partial response during the triptorelin-containing combination.

    In plain wordsIn resistant melanoma, one patient receiving the triptorelin-containing combination had a partial tumor response under RECIST criteria.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableRECIST partial response
    Study

    n = 14

    Outcome group
    Tumor growth · Cancer

    Measurements

    Patients with RECIST partial response
    1 patients
    RECIST v1.1

    Source sentences

    Summary
    According to RECIST v1.1, best overall response was partial response (PR) in one patient with a pancreas metastasis, stable disease (SD) in 5 patients, and progressive disease in 8 patients.
    2 context sentences
    Summary · context
    This phase I study evaluated the safety, efficacy, and pharmocodynamics of androgen deprivation with the gonadotropin releasing hormone (GnRH) agonist triptorelin combined with nivolumab in male patients with melanoma resistant to anti-PD-1.
    Summary · context
    Adult male patients with advanced melanoma who progressed under anti-PD-1 containing regimens received triptorelin 3.75 mg every 4 weeks, nivolumab 3 mg/kg every 2 weeks, and bicalutamide 50 mg once daily during the first 28 days.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  4. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In resistant melanoma, five patients receiving the triptorelin-containing combination had stable disease under RECIST criteria.

    In plain wordsIn resistant melanoma, five patients receiving the triptorelin-containing combination had stable disease under RECIST criteria.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableRECIST stable disease
    Study

    n = 14

    Outcome group
    Tumor growth · Cancer

    Measurements

    Patients with RECIST stable disease
    5 patients
    RECIST v1.1

    Source sentences

    Summary
    According to RECIST v1.1, best overall response was partial response (PR) in one patient with a pancreas metastasis, stable disease (SD) in 5 patients, and progressive disease in 8 patients.
    2 context sentences
    Summary · context
    This phase I study evaluated the safety, efficacy, and pharmocodynamics of androgen deprivation with the gonadotropin releasing hormone (GnRH) agonist triptorelin combined with nivolumab in male patients with melanoma resistant to anti-PD-1.
    Summary · context
    Adult male patients with advanced melanoma who progressed under anti-PD-1 containing regimens received triptorelin 3.75 mg every 4 weeks, nivolumab 3 mg/kg every 2 weeks, and bicalutamide 50 mg once daily during the first 28 days.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  5. 05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In resistant melanoma, eight patients receiving the triptorelin-containing combination had progressive disease under RECIST criteria.

    In plain wordsIn resistant melanoma, eight patients receiving the triptorelin-containing combination had progressive disease under RECIST criteria.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableRECIST progressive disease
    Study

    n = 14

    Outcome group
    Tumor growth · Cancer

    Measurements

    Patients with RECIST progressive disease
    8 patients
    RECIST v1.1

    Source sentences

    Summary
    According to RECIST v1.1, best overall response was partial response (PR) in one patient with a pancreas metastasis, stable disease (SD) in 5 patients, and progressive disease in 8 patients.
    2 context sentences
    Summary · context
    This phase I study evaluated the safety, efficacy, and pharmocodynamics of androgen deprivation with the gonadotropin releasing hormone (GnRH) agonist triptorelin combined with nivolumab in male patients with melanoma resistant to anti-PD-1.
    Summary · context
    Adult male patients with advanced melanoma who progressed under anti-PD-1 containing regimens received triptorelin 3.75 mg every 4 weeks, nivolumab 3 mg/kg every 2 weeks, and bicalutamide 50 mg once daily during the first 28 days.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  6. 06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In resistant melanoma, an additional partial response followed initial pseudoprogression under iRECIST with the triptorelin-containing combination.

    In plain wordsIn resistant melanoma, an additional partial response followed initial pseudoprogression under iRECIST with the triptorelin-containing combination.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableAdditional iRECIST partial response
    Study

    n = 14

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    According to iRECIST, a second PR occurred after an initial pseudoprogression, TRECs increased in 2 patients, one with PR who also had an increase in TILs, and the second with SD.
    2 context sentences
    Summary · context
    This phase I study evaluated the safety, efficacy, and pharmocodynamics of androgen deprivation with the gonadotropin releasing hormone (GnRH) agonist triptorelin combined with nivolumab in male patients with melanoma resistant to anti-PD-1.
    Summary · context
    Adult male patients with advanced melanoma who progressed under anti-PD-1 containing regimens received triptorelin 3.75 mg every 4 weeks, nivolumab 3 mg/kg every 2 weeks, and bicalutamide 50 mg once daily during the first 28 days.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  7. 07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialMechanism

    In resistant melanoma, T-cell receptor excision circles increased in two patients receiving the triptorelin-containing combination.

    In plain wordsIn resistant melanoma, a marker of thymus activity increased in two patients receiving the triptorelin-containing combination.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseT-cell receptor excision circles
    Study

    n = 14

    Outcome group
    Immune response · Immune and inflammation

    Measurements

    Patients with increased TREC
    2 patients
    combination regimen

    Source sentences

    Summary
    According to iRECIST, a second PR occurred after an initial pseudoprogression, TRECs increased in 2 patients, one with PR who also had an increase in TILs, and the second with SD.
    2 context sentences
    Summary · context
    This phase I study evaluated the safety, efficacy, and pharmocodynamics of androgen deprivation with the gonadotropin releasing hormone (GnRH) agonist triptorelin combined with nivolumab in male patients with melanoma resistant to anti-PD-1.
    Summary · context
    Adult male patients with advanced melanoma who progressed under anti-PD-1 containing regimens received triptorelin 3.75 mg every 4 weeks, nivolumab 3 mg/kg every 2 weeks, and bicalutamide 50 mg once daily during the first 28 days.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  8. 08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In anti-PD-1-resistant melanoma, disease control occurred in 42.8% with triptorelin, nivolumab, and initial bicalutamide under RECIST criteria.

    In plain wordsIn resistant melanoma, disease control occurred in 42.8% with triptorelin, nivolumab, and initial bicalutamide under RECIST criteria.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableRECIST disease control
    Study

    n = 14

    Outcome group
    Tumor growth · Cancer

    Measurements

    Disease control
    42.8%
    RECIST

    Source sentences

    Summary
    Disease control was obtained in 42.8% (RECIST) and 50% (iRECIST).
    2 context sentences
    Summary · context
    According to RECIST v1.1, best overall response was partial response (PR) in one patient with a pancreas metastasis, stable disease (SD) in 5 patients, and progressive disease in 8 patients.
    Summary · context
    Adult male patients with advanced melanoma who progressed under anti-PD-1 containing regimens received triptorelin 3.75 mg every 4 weeks, nivolumab 3 mg/kg every 2 weeks, and bicalutamide 50 mg once daily during the first 28 days.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  9. 09HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In anti-PD-1-resistant melanoma, disease control occurred in 50% with triptorelin, nivolumab, and initial bicalutamide under iRECIST criteria.

    In plain wordsIn resistant melanoma, disease control occurred in 50% with triptorelin, nivolumab, and initial bicalutamide under iRECIST criteria.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableiRECIST disease control
    Study

    n = 14

    Outcome group
    Tumor growth · Cancer

    Measurements

    Disease control
    50%
    iRECIST

    Source sentences

    Summary
    Disease control was obtained in 42.8% (RECIST) and 50% (iRECIST).
    3 context sentences
    Summary · context
    According to RECIST v1.1, best overall response was partial response (PR) in one patient with a pancreas metastasis, stable disease (SD) in 5 patients, and progressive disease in 8 patients.
    Summary · context
    According to iRECIST, a second PR occurred after an initial pseudoprogression, TRECs increased in 2 patients, one with PR who also had an increase in TILs, and the second with SD.
    Summary · context
    Adult male patients with advanced melanoma who progressed under anti-PD-1 containing regimens received triptorelin 3.75 mg every 4 weeks, nivolumab 3 mg/kg every 2 weeks, and bicalutamide 50 mg once daily during the first 28 days.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  10. 10HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialMechanism

    In resistant melanoma, tumor-infiltrating lymphocytes increased in one partial responder receiving the triptorelin-containing combination.

    In plain wordsIn resistant melanoma, immune cells within the tumor increased in one partial responder receiving the triptorelin-containing combination.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseTumor-infiltrating lymphocytes
    Study

    n = 1

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    According to iRECIST, a second PR occurred after an initial pseudoprogression, TRECs increased in 2 patients, one with PR who also had an increase in TILs, and the second with SD.
    2 context sentences
    Summary · context
    This phase I study evaluated the safety, efficacy, and pharmocodynamics of androgen deprivation with the gonadotropin releasing hormone (GnRH) agonist triptorelin combined with nivolumab in male patients with melanoma resistant to anti-PD-1.
    Summary · context
    Adult male patients with advanced melanoma who progressed under anti-PD-1 containing regimens received triptorelin 3.75 mg every 4 weeks, nivolumab 3 mg/kg every 2 weeks, and bicalutamide 50 mg once daily during the first 28 days.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.